Roquefort Therapeutics Rebrands as Coiled Therapeutics After AO-252 Licence Deal

Roquefort Investments PLC ( (GB:ROQ) ) has shared an announcement.

Roquefort Therapeutics has received shareholder approval to acquire the exclusive worldwide licence for AO-252 from Coiled Therapeutics, Inc. and to change its name to Coiled Therapeutics plc, effective 27 March 2026. To update and engage investors on these strategic developments, the leadership team will host a live interactive presentation on the Engage Investor platform on 30 March 2026, inviting current shareholders and prospective investors to participate and submit questions.

The most recent analyst rating on (GB:ROQ) stock is a Sell with a £1.00 price target. To see the full list of analyst forecasts on Roquefort Investments PLC stock, see the GB:ROQ Stock Forecast page.

Spark’s Take on ROQ Stock

According to Spark, TipRanks’ AI Analyst, ROQ is a Neutral.

The score is primarily held back by weak financial fundamentals (pre-commercial revenue volatility, ongoing losses and cash burn). Technical indicators also point to a sustained downtrend. Low leverage on the balance sheet provides some support, but the negative P/E and lack of dividend yield limit valuation appeal.

To see Spark’s full report on ROQ stock, click here.

More about Roquefort Investments PLC

Roquefort Therapeutics plc, soon to be renamed Coiled Therapeutics plc, is a Main Market-listed biotechnology company on the London Stock Exchange. The company focuses on developing innovative therapeutic assets, and its strategy includes acquiring exclusive licences to expand its drug pipeline and strengthen its position in the biotech sector.

Average Trading Volume: 955,481

Technical Sentiment Signal: Sell

Current Market Cap: £1.64M

See more insights into ROQ stock on TipRanks’ Stock Analysis page.